Literature DB >> 28396500

Percutaneous Pericardial Resection: A Novel Potential Treatment for Heart Failure With Preserved Ejection Fraction.

Barry A Borlaug1, Rickey E Carter2, Vojtech Melenovsky2, Christopher V DeSimone2, Prakriti Gaba2, Ammar Killu2, Niyada Naksuk2, Lilach Lerman2, Samuel J Asirvatham2.   

Abstract

BACKGROUND: People with heart failure and preserved ejection fraction develop increases in left ventricular (LV) end-diastolic pressures during exercise that contribute to dyspnea. In normal open-chest animal preparations, the pericardium restrains LV filling when central blood volume increases. We hypothesized that resection of the pericardium using a minimally invasive epicardial approach would mitigate the increase in LV end-diastolic pressure that develops during volume loading in normal and diseased hearts with the chest intact. METHODS AND
RESULTS: Invasive hemodynamic assessment was performed at baseline and after saline load before and after pericardial resection in normal canines with open (n=3) and closed chest (n=5) and in a pig model with features of human heart failure and preserved ejection fraction with sternum intact (n=4). In closed-chest animals, pericardiotomy was performed using a novel subxiphoid procedure. In both experimental preparations of normal dogs, pericardiotomy blunted the increase in LV end-diastolic pressure with saline infusion, while enhancing the saline-mediated increase in LV end-diastolic volume. With chest intact in the pig model, percutaneous pericardial resection again blunted the increase in LV end-diastolic pressure secondary to volume expansion (+4±3 versus +13±5 mm Hg; P=0.014), while enhancing the saline-mediated increase in LV end-diastolic volume (+17±1 versus +10±2 mL; P=0.016).
CONCLUSIONS: This proof of concept study demonstrates that pericardial resection through a minimally invasive percutaneous approach mitigates the elevation in LV filling pressures with volume loading in both normal animals and a pig model with diastolic dysfunction. Further study is warranted to determine whether this method is safe and produces similar acute and chronic hemodynamic benefits in people with heart failure and preserved ejection fraction.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  blood volume; heart failure; hemodynamics; humans; pericardium

Mesh:

Year:  2017        PMID: 28396500      PMCID: PMC5390814          DOI: 10.1161/CIRCHEARTFAILURE.116.003612

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  32 in total

1.  Heart size and maximal cardiac output are limited by the pericardium.

Authors:  H K Hammond; F C White; V Bhargava; R Shabetai
Journal:  Am J Physiol       Date:  1992-12

Review 2.  Correlative anatomy for the electrophysiologist, Part I: the pericardial space, oblique sinus, transverse sinus.

Authors:  Nirusha Lachman; Faisal F Syed; Ammar Habib; Suraj Kapa; Susan E Bisco; K L Venkatachalam; Samuel J Asirvatham
Journal:  J Cardiovasc Electrophysiol       Date:  2010-08-19

3.  Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.

Authors:  Shmuel Schwartzenberg; Margaret M Redfield; Aaron M From; Paul Sorajja; Rick A Nishimura; Barry A Borlaug
Journal:  J Am Coll Cardiol       Date:  2012-01-31       Impact factor: 24.094

4.  Restraining effect of intact pericardium during acute volume loading.

Authors:  R J Applegate; W E Johnston; J Vinten-Johansen; H S Klopfenstein; W C Little
Journal:  Am J Physiol       Date:  1992-06

5.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.

Authors:  Vojtech Melenovsky; Barry A Borlaug; Boaz Rosen; Ilan Hay; Luigi Ferruci; Christopher H Morell; Edward G Lakatta; Samer S Najjar; David A Kass
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

6.  External pressure of undisturbed left ventricle.

Authors:  R J Applegate; W P Santamore; H S Klopfenstein; W C Little
Journal:  Am J Physiol       Date:  1990-04

7.  Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease.

Authors:  Victor H Urbieta-Caceres; Xiang-Yang Zhu; Kyra L Jordan; Hui Tang; Kyle Textor; Amir Lerman; Lilach O Lerman
Journal:  Atherosclerosis       Date:  2011-10-12       Impact factor: 5.162

8.  Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Rick A Nishimura; Paul Sorajja; Carolyn S P Lam; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2010-06-11       Impact factor: 8.790

Review 9.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

10.  Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Wissam A Jaber; Steve R Ommen; Carolyn S P Lam; Margaret M Redfield; Rick A Nishimura
Journal:  Heart       Date:  2011-04-08       Impact factor: 5.994

View more
  23 in total

1.  Pericardiotomy Enhances Left Ventricular Diastolic Reserve With Volume Loading in Humans.

Authors:  Barry A Borlaug; Hartzell V Schaff; Alberto Pochettino; Dawn M Pedrotty; Samuel J Asirvatham; Martin D Abel; Rickey E Carter; William J Mauermann
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

2.  Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.

Authors:  Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

Review 3.  Translation to Practice: Accelerating the Cycle of Innovation to Impact.

Authors:  Jeff R Anderson; Thomas D Y Chung; Leon Clark; Jennifer A Weis; Andrew J Danielsen; Sundeep Khosla; Gregory J Gores; Andrew D Badley
Journal:  Mayo Clin Proc       Date:  2019-02-07       Impact factor: 7.616

Review 4.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

5.  The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Brandon Wiley; Katlyn E Koepp; Caitlin C Jorgenson; Alexander Egbe; Vojtech Melenovsky; Rickey E Carter; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

6.  Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2018-05-23       Impact factor: 12.035

Review 7.  Diastolic Stress Testing Along the Heart Failure Continuum.

Authors:  T Jake Samuel; Rhys Beaudry; Satyam Sarma; Vlad Zaha; Mark J Haykowsky; Michael D Nelson
Journal:  Curr Heart Fail Rep       Date:  2018-12

Review 8.  The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment.

Authors:  Barry A Borlaug; Yogesh N V Reddy
Journal:  JACC Heart Fail       Date:  2019-07       Impact factor: 12.035

9.  Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.

Authors:  Yogesh N V Reddy; Masaru Obokata; Frederik H Verbrugge; Grace Lin; Barry A Borlaug
Journal:  J Am Coll Cardiol       Date:  2020-09-01       Impact factor: 24.094

10.  20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.

Authors:  Sanjiv J Shah
Journal:  J Am Soc Echocardiogr       Date:  2019-11       Impact factor: 5.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.